推荐产品
技術
HPLC: suitable
品質等級
雜質
DNases, none detected
RNases, none detected
phosphatases, none detected
proteases, none detected
適合性
corresponds for identity (HPLC)
儲存溫度
2-8°C
應用
使用BioStab抗体稳定剂可以防止抗体降解。添加BioStab抗体稳定剂可延长抗体的使用寿命和包被率。BioStab抗体稳定剂可用于ELISA、蛋白质免疫印迹、免疫组织化学以及其他需要标记物或生物素化抗体的应用。该稳定剂的表面活性剂含量极低。
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
其他客户在看
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(11), 3247-3258 (2019-02-20)
Immunotherapies targeting costimulating and coinhibitory checkpoint receptors beyond PD-1 and CTLA-4 have entered clinical trials. Little is known about the relative abundance, coexpression, and immune cells enriched for each specific drug target, limiting understanding of the biological basis of potential
Optometry and vision science : official publication of the American Academy of Optometry, 82(3), 209-214 (2005-03-16)
Lysozyme deposits extracted from lotrafilcon silicone hydrogel (SH) contact lens materials demonstrate a loss in total mass as a function of storage time when assessed by Western blotting. This loss represents a potential source of error when quantifying total lysozyme
Current protein & peptide science, 11(8), 744-751 (2011-01-18)
Biomedical applications of osmolytes, including stabilization of protein-based pharmaceutics, preservation of living biological material and potential therapeutic prescription in vivo, are intimately related to the fact that osmolytes favour the native structure of proteins. The shift towards the native structure
Journal of immunological methods, 180(2), 237-245 (1995-03-27)
A two step simple procedure for antibody stabilization in soluble form was developed. The antibody is first treated with low molecular weight polyaldehyde (polyglutaraldehyde). Following removal of non-bound polyaldehyde the antibody-polyaldehyde conjugate is crosslinked by polyamine (alkyl amine derivative of
Advanced drug delivery reviews, 63(13), 1086-1106 (2011-09-13)
Aggregation is arguably the biggest challenge for the development of stable formulations and robust manufacturing processes of therapeutic proteins. In search of novel excipients inhibiting protein aggregation, cyclodextrins and their derivatives have been under examination for use in parenteral protein
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门